GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (LTS:0JXI) » Definitions » PB Ratio

Madrigal Pharmaceuticals (LTS:0JXI) PB Ratio : 9.23 (As of Apr. 16, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Madrigal Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-16), Madrigal Pharmaceuticals's share price is $316.53. Madrigal Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2024 was $34.28. Hence, Madrigal Pharmaceuticals's PB Ratio of today is 9.23.

Warning Sign:

Madrigal Pharmaceuticals Inc stock PB Ratio (=9.4) is close to 1-year high of 10.16.

The historical rank and industry rank for Madrigal Pharmaceuticals's PB Ratio or its related term are showing as below:

LTS:0JXI' s PB Ratio Range Over the Past 10 Years
Min: 5.38   Med: 8.72   Max: 10.16
Current: 9.18

During the past 13 years, Madrigal Pharmaceuticals's highest PB Ratio was 10.16. The lowest was 5.38. And the median was 8.72.

LTS:0JXI's PB Ratio is ranked worse than
89.25% of 1284 companies
in the Biotechnology industry
Industry Median: 2.1 vs LTS:0JXI: 9.18

During the past 12 months, Madrigal Pharmaceuticals's average Book Value Per Share Growth Rate was 68.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 44.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 5.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Madrigal Pharmaceuticals was 107.00% per year. The lowest was -51.20% per year. And the median was 3.80% per year.

Back to Basics: PB Ratio


Madrigal Pharmaceuticals PB Ratio Historical Data

The historical data trend for Madrigal Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals PB Ratio Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.63 7.49 27.42 11.34 9.18

Madrigal Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.34 6.49 7.10 6.12 9.18

Competitive Comparison of Madrigal Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Madrigal Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's PB Ratio falls into.


;
;

Madrigal Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Madrigal Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=316.53/34.282
=9.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Madrigal Pharmaceuticals  (LTS:0JXI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Madrigal Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Headlines

No Headlines